Inactive Instrument

Pharmiva AB (publ)

PHARM

SE0015530670

Pharmiva AB has filed an IPO.

March 04, 2021 at 12:00 am EST

Pharmiva AB (publ) has filed an IPO. Security Name: Shares Security Type: Common Stock

Latest news about Pharmiva AB (publ)

PEPTONIC medical AB completed the acquisition of Pharmiva AB (OM : PHARM).	Nov. 20	CI
Walmart Starts Selling Peptonic's Products in the US	23-10-10	CI
Pharmiva Accepts Peptonic Merger for Creation of Global Femtech Company	23-08-21	MT
Pharmiva AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-16	CI
Women’s Health Companies Peptonic, Pharmiva to Merge	23-06-15	MT
Pharmiva AB (OM:PHARM) entered in the letter of intent to acquire PEPTONIC medical AB.	23-06-14	CI
Pharmiva AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-24	CI
Pharmiva AB Auditor Raises 'Going Concern' Doubt	23-04-19	CI
1,317,516 Shares of Pharmiva AB are subject to a Lock-Up Agreement Ending on 25-MAR-2023.	23-03-24	CI
Pharmiva AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-02-22	CI
Pharmiva AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-16	CI
Pharmiva AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-17	CI
Pharmiva AB Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-11	CI
Pharmiva AB announced that it has received SEK 1.2 million in funding	22-04-11	CI
Pharmiva AB has completed an IPO in the amount of SEK 35 million.	21-03-31	CI
Pharmiva AB has filed an IPO.	21-03-04	CI

Pharmiva AB (publ) is a Sweden-based medical technology company within FemTech that is focused on research and development of medical products. Pharmiva AB (publ) aims to improve vaginal health and reduce the risk of complications by offering treatments without antibiotics. The company's first product Vernivia is antibiotic- and prescription-free treatment for bacterial vaginosis (BV). The treatment is based on Pharmiva AB's (publ) patented drug delivery platform, Venerol, which contains naturally occurring ingredients. The company has received CE marking class IIa for Vernivia, which means that Pharmiva AB (publ) has the right to sell and market the product within the EEA. Pharmiva AB (publ) is also ISO-certified according to ISO 13485 current design, production, marketing and sales.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+24.60%	672B
NOVO NORDISK A/S	+24.08%	550B
JOHNSON & JOHNSON	-5.63%	351B
MERCK & CO., INC.	+15.37%	317B
ABBVIE INC.	+7.38%	292B
ASTRAZENECA PLC	+3.26%	211B
NOVARTIS AG	+0.78%	203B
PFIZER, INC.	-9.69%	144B
AMGEN INC.	-6.63%	141B

Other Pharmaceuticals